专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2019112552A1 CROMOLYN COMPOSITIONS AND METHODS THEREOF 审中-公开
公开(公告)号：WO2019112552A1
公开(公告)日：2019-06-13
申请号：PCT/US2017/064526
申请日：2017-12-28
申请人： AZTHERAPIES, INC , ELMALEH, David R.
发明人： ELMALEH, David R.
IPC分类号： A61K31/192 , A61K31/352 , A61K9/14
CPC分类号： A61K31/352 , A61K9/0075
摘要： Methods of delivering cromolyn to a patient in need thereof, methods of treating amyloid-associated conditions and inflammatory or allergic lung diseases, and packs and kits comprising cromolyn are described.

2. 发明申请

WO2017132601A1 DRY POWDER INHALER 审中-公开
标题翻译：干粉吸入器
公开(公告)号：WO2017132601A1
公开(公告)日：2017-08-03
申请号：PCT/US2017/015486
申请日：2017-01-27
申请人： MANNKIND CORPORATION
发明人： KINSEY, P. Spencer , LAURENZI, Brendan , SMUTNEY, Chad, C. , ADAMO, Benoit , GUARNERI, Joseph
IPC分类号： A61K9/00 , A61M15/00
CPC分类号： A61M15/0021 , A61K9/0075 , A61K31/137 , A61K31/352 , A61K31/473 , A61K31/495 , A61K31/5575 , A61K31/661 , A61M15/0025 , A61M15/0028 , A61M15/0045 , A61M15/0091 , A61M2202/064 , A61M2205/10 , A61M2205/121 , A61M2205/128 , A61M2205/583 , A61M2206/14 , A61M2207/00 , A61K2300/00
摘要： A dry powder inhaler including replaceable cartridges containing a dry powder for local or systemic delivery through the pulmonary tract and lungs is disclosed. The inhalers are used with inhalable dry powders, including medicament formulations comprising active agents for local or systemic delivery and for the treatment of diseases such as, pulmonary hypertension, cardiovascular disease, anaphylaxis, diabetes, obesity, cancer, and other diseases, or symptoms associated with these and other diseases, such as nausea, vomiting, pain and inflammation.
摘要翻译：公开了一种干粉吸入器，其包括含有干粉的可替换药筒，用于局部或全身递送通过肺道和肺。吸入器与可吸入干粉一起使用，包括药物制剂，其包含用于局部或全身递送的活性剂和用于治疗诸如肺高血压，心血管疾病，过敏反应，糖尿病，肥胖症，癌症和其他疾病或与症状有关的疾病与这些和其他疾病，如恶心，呕吐，疼痛和炎症。

3. 发明申请

WO2017085007A1 A PROCESS FOR PREPARING A DRY POWDER FORMULATION COMPRISING AN ANTICHOLINERGIC, A CORTICOSTEROID AND A BETA-ADRENERGIC 审中-公开
标题翻译：制备包含抗胆碱能剂，皮质类固醇和β肾上腺素能制剂的干粉制剂的方法
公开(公告)号：WO2017085007A1
公开(公告)日：2017-05-26
申请号：PCT/EP2016/077566
申请日：2016-11-14
申请人： CHIESI FARMACEUTICI S.P.A.
发明人： CAFIERO, Claudio , ORTENZI, Leonardo
IPC分类号： A61K47/12 , A61K9/00 , A61K47/26 , A61K9/14 , A61K31/00
CPC分类号： A61K31/57 , A61K9/0075 , A61K9/145 , A61K9/1617 , A61K9/1623 , A61K31/00 , A61K31/167 , A61K31/40 , A61K47/12 , A61K47/26
摘要： The invention relates to a dry powder formulation for inhalation comprising a combination of an anti-cholinergic, a long-acting beta 2 -adrenoceptor agonist, and,optionally, an inhaled corticosteroid, and to a process for preparation thereof.
摘要翻译：本发明涉及用于吸入的干粉制剂，其包含抗胆碱能药，长效β2肾上腺素受体激动剂和任选的吸入剂的组合皮质类固醇，以及其制备方法。

4. 发明申请

WO2015189579A9 IMPROVEMENTS TO NASAL COMPOSITIONS AND METHOD OF USE THEREOF 审中-公开
标题翻译：对NASAL组合物的改进及其使用方法
公开(公告)号：WO2015189579A9
公开(公告)日：2017-02-23
申请号：PCT/GB2015051661
申请日：2015-06-08
申请人： NASALEZE PATENTS LTD
发明人： POPOV TODOR A
IPC分类号： A61K9/00 , A61K47/38
CPC分类号： A61K31/4174 , A23L33/10 , A23V2002/00 , A61K9/0043 , A61K9/0075 , A61K9/0078 , A61K9/1652 , A61K47/38 , A61M11/00 , A61M15/08 , A61M2202/04 , A61M2202/064
摘要： A nasal composition is provided comprising or consisting of a first composition part in the form of a liquid for nasal application to a patient in use, and a second composition part in the form of a powder for nasal application to the patient in use. The first and second composition parts are applied to the patient separately or together as required.
摘要翻译：提供了一种鼻组合物，其包括由用于鼻用于施用于使用的患者的液体形式的第一组合物部分或由使用中的鼻施用的粉末形式的第二组合物部分组成。根据需要将第一和第二组合物单独地或一起应用于患者。

5. 发明申请

WO2016180483A1 ONCE-DAILY TREATMENT OF PULMONARY FIBROSIS 审中-公开
标题翻译：每日治疗肺动脉硬化
公开(公告)号：WO2016180483A1
公开(公告)日：2016-11-17
申请号：PCT/EP2015/060456
申请日：2015-05-12
申请人： GALECTO BIOTECH AB
发明人： SCHAMBYE, Hans , PEDERSEN, Anders , FORD, Paul
IPC分类号： A61K31/4192 , A61K31/055 , A61P11/00
CPC分类号： A61K31/7056 , A61K9/0075 , A61K31/055 , A61K31/4192 , A61P11/00
摘要： The present invention relates to a compound of formula (I) for use in a method for treatment of pulmonary fibrosis in a human comprising administering once-a-day to the narrowest parts of the lung tissue of the human an amount of the compound of formula (I) effective to treat said pulmonary fibrosis.
摘要翻译：本发明涉及用于治疗人类肺纤维化的方法中的式（I）化合物，其包括每天一次给予人的肺组织最窄部分一定量的式（I）有效治疗所述肺纤维化。

6. 发明申请

WO2016176423A1 NOVEL PRODRUGS OF DITHIOL MUCOLYTIC AGENTS 审中-公开
标题翻译： DITHIOL MUCOLYTIC代理商的新产品
公开(公告)号：WO2016176423A1
公开(公告)日：2016-11-03
申请号：PCT/US2016/029729
申请日：2016-04-28
申请人： PARION SCIENCES, INC.
发明人： JOHNSON, Michael, Ross , THELIN, William, R.
IPC分类号： A61K31/145 , A61K31/14 , C07C323/16
CPC分类号： C07C327/28 , A61K9/0075 , A61K9/16 , A61K31/047 , A61K31/133 , A61K31/265 , A61K31/341 , A61K31/385 , A61K31/683 , A61K33/14 , C07C323/16 , C07C327/22 , C07D307/68 , C07D339/00 , C07D339/08 , C07F9/65785 , C12N9/0071 , C12N9/0073 , C12N9/1051 , C12N9/13 , C12P17/165 , C12P19/60 , C12Y114/13008 , C12Y114/14001 , C12Y208/02001
摘要： Provided are mucolytic compounds that are more effective, and/or absorbed less rapidly from mucosal surfaces, and/or are better tolerated as compared to N-acetylcysteine (NAC) and DTT. The compounds are represented by compounds of Formula I which embrace structures (la)-(Ib), where the structural variables are as defined herein.
摘要翻译：提供了比N-乙酰半胱氨酸（NAC）和DTT相比更有效和/或从粘膜表面迅速吸收的和/或更好的耐受性的粘液溶解化合物。化合物由式I化合物表示，其包含结构（Ia） - （Ib），其中结构变量如本文所定义。

7. 发明申请

WO2016160370A1 HAND-ACTUATED DRY POWDER INHALER AND ITS USE 审中-公开
标题翻译：手动干燥粉末吸入器及其使用
公开(公告)号：WO2016160370A1
公开(公告)日：2016-10-06
申请号：PCT/US2016/023058
申请日：2016-03-18
申请人： LIU, James Zhou , GU, Yuehua
发明人： LIU, James Zhou , GU, Yuehua
IPC分类号： A01M15/00
CPC分类号： A61M16/14 , A61K9/0075 , A61K9/14 , A61M11/003 , A61M11/02 , A61M15/0015 , A61M15/0021 , A61M15/003 , A61M15/0035 , A61M15/0045 , A61M15/0048 , A61M15/0086 , A61M2202/064 , A61M2205/075 , A61M2206/16
摘要： Disclosed herein are inhalers, having an airflow chamber (8) for receiving air from an inlet channel and holding a medicament in powder form, the chamber (8) forming a starting section of an air passage (4) and including a turbulence generating mechanism that generates turbulent air flow through the chamber (8) such that during use of the inhaler, the air flow causes vibration of a holder (31) received by the chamber (8) to assist in releasing the medicament; a positive pressure supplier (2) connected to the chamber (8) for triggering and driving the medicament through the air passage towards a mouthpiece (6); a closure means (3.1, 3.2) that closes the airflow chamber (8) to form an air passage; a piercing element (1) coupled to the airflow chamber (8) to pierce the holder and release the medicament into the air passage; and an outlet air channel that connects to the chamber (8).
摘要翻译：这里公开了一种吸入器，其具有用于从入口通道接收空气并保持粉末形式的药物的气流室（8），腔室（8）形成空气通道（4）的起始部分，并且包括湍流发生机构，产生通过所述腔室（8）的湍流空气流，使得在使用所述吸入器期间，所述空气流引起由所述腔室（8）容纳的保持器（31）的振动以帮助释放所述药物; 连接到所述室（8）的正压供应器（2），用于通过所述空气通道朝向接口（6）触发和驱动药物; 关闭气流室（8）以形成空气通道的封闭装置（3.1,3.2）; 连接到所述气流室（8）的刺穿元件（1）以刺穿所述保持器并将所述药物释放到所述空气通道中; 以及连接到所述室（8）的出口空气通道。

8. 发明申请

WO2016130645A1 RAPAMYCIN FOR THE TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS 审中-公开
标题翻译：用于治疗淋巴细胞白血病的RAPAMYCIN
公开(公告)号：WO2016130645A1
公开(公告)日：2016-08-18
申请号：PCT/US2016/017304
申请日：2016-02-10
申请人： LAM THERAPEUTICS, INC.
发明人： ARMER, Thomas , MELVIN, Lawrence, S., Jr. , ROTHBERG, Jonathan, M. , LICHENSTEIN, Henri
IPC分类号： A61K31/436 , A61K9/16 , A61P11/00
CPC分类号： A61K31/436 , A61K9/0075 , A61K9/1623
摘要： The present invention relates to pharmaceutical aerosol formulations of rapamycin effective to achieve therapeutic levels of rapamycin in the lung concomitantly with low systemic exposure to drug, and therapeutic methods relating to same.
摘要翻译：本发明涉及雷帕霉素的药物气雾剂制剂，其有效地在肺中达到治疗水平的雷帕霉素，同时伴随着全身暴露于药物，以及与其相关的治疗方法。

9. 发明申请

WO2016118589A1 DRY POWDER INHALER COMPRISING FLUTICASONE PROPIONATE AND SALMETEROL XINAFOAT 审中-公开
标题翻译：含有氟啶酮和硫代麦芽兰糖的干粉吸入剂
公开(公告)号：WO2016118589A1
公开(公告)日：2016-07-28
申请号：PCT/US2016/014072
申请日：2016-01-20
申请人： TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC.
发明人： DALVI, Mukul , TEE, Seah, Kee
IPC分类号： A61K9/00 , A61K31/137 , A61K31/56 , A61P11/00
CPC分类号： A61K9/0075 , A61K31/137 , A61K31/138 , A61K31/56 , A61K47/26 , A61M15/0005 , A61M15/0008 , A61M15/0021 , A61M16/14 , A61M2202/064 , A61K2300/00
摘要： This invention provides a dry powder inhaler comprising : a dry powder medicament comprising fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of fluticasone propionate per actuation is less than 100 μg; and wherein the dose provides a baseline-adjusted FEV 1 in a patient of more than 150 mL within 30 minutes of receiving the dose. A method of treating a patient includes administering to a patient a dry powder medicament having fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of fluticasone propionate per actuation is less than 100 pg; and wherein the dose provides a baseline-adjusted FEV 1 in a patient of more than 150 mL within 30 minutes of receiving the dose.
摘要翻译：本发明提供一种干粉吸入器，其包括：干粉药物，其包含丙酸氟替卡松，硫酸沙美特罗和乳糖载体; 其中，每次致动的丙酸氟替卡松的递送剂量小于100μg; 并且其中所述剂量在接受剂量的30分钟内提供大于150mL患者的基线调整的FEV1。治疗患者的方法包括向患者施用具有丙酸氟替卡松，硫酸沙美特罗和乳糖载体的干粉药物; 其中，每次致动的丙酸氟替卡松的递送剂量小于100pg; 并且其中所述剂量在接受剂量的30分钟内提供大于150mL患者的基线调整的FEV1。

10. 发明申请

WO2016113216A1 PHARMACEUTICAL COMBINATION 审中-公开
标题翻译：药物组合
公开(公告)号：WO2016113216A1
公开(公告)日：2016-07-21
申请号：PCT/EP2016/050370
申请日：2016-01-11
申请人： GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
发明人： FISH, Colin John
IPC分类号： A61K9/00 , A61K31/4709 , A61K31/58 , A61P11/08
CPC分类号： A61K31/58 , A61K9/0075 , A61K31/4709 , A61K2300/00
摘要： This invention provides a pharmaceutical combination comprising biphenyl-2-ylcarbamic acid 1-[2-(2- chloro-4-{[( R )-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]methyl}-5-methoxyphenylcarbamoyl)ethyl]piperidin-4-yl ester, or a pharmaceutically acceptable salt thereof, and fluticasone furoate, and use of the pharmaceutical combination in therapy, for example in the treatment or prophylaxis of respiratory disorders or diseases, for example pulmonary disorders such as chronic obstructive pulmonary disease (COPD) asthma and Asthma-COPD Overlap Syndrome (ACQS).
摘要翻译：本发明提供药物组合，其包含联苯-2-基氨基甲酸1- [2-（2-氯-4 - {[（R）-2-羟基-2-（8-羟基-2-氧代-1,2- 二氢喹啉-5-基）乙基氨基]甲基} -5-甲氧基苯基氨基甲酰基）乙基]哌啶-4-基酯或其药学上可接受的盐和氟替卡松糠酸酯，以及药物组合在治疗中的用途，例如在治疗或预防呼吸系统疾病或疾病，例如慢性阻塞性肺疾病（COPD）哮喘和哮喘 - COPD重叠综合征（ACQS）等肺病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式